NOTCH3
Neurogenic locus notch homolog protein 3
As of the edition of 20 October 2026, NOTCH3 (neurogenic locus notch homolog protein 3, UniProt Q9UM47) has 2 drugs tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9UM47
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 6
- Disease areas
- Cancer; Digestive system; Hormones; Lungs and airways; Skin and connective tissue
- Registered trials of its drugs
- 4
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tarextumab | Stopped | Phase 2 | none listed |
| PF-06650808 | Stopped | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Pfizer | Route A |
| Mereo BioPharma | Route A |
The other 0 companies at NOTCH3
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at NOTCH3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.